hVEGF-IN-1 is a quinazoline derivative (IRES-A: Kd = 0.928μM) [1]. By reducing VEGF-A protein expression, hVEGF-IN-1 effectively blocks tumor cell migration and inhibits tumor growth [2]. hVEGF-IN-1 is primarily used to study VEGF-A-mediated tumor angiogenesis [3].
In MDA-MB-231 cells, hVEGF-IN-1 (0.375-3μM; 24h) reduced cell migration by approximately 25% [1]. In K562 cells, hVEGF-IN-1 (5μM; 24h) upregulates the expression of miR-let-7a and inhibits the translation of VEGF-A [4]. In NRK52E cells, hVEGF-IN-1 (5μM; 4h) inhibits VEGF-A expression [5].
References:
[1]. Wang S K, Wu Y, Wang X Q, et al. Discovery of Small Molecules for Repressing Cap-Independent Translation of Human Vascular Endothelial Growth Factor (h VEGF) as Novel Antitumor Agents[J]. Journal of Medicinal Chemistry, 2017, 60(13): 5306-5319.
[2]. Donlic A, Comi T J, Quinodoz S A, et al. Deep Learning of Functional Perturbations from Condensate Morphology[J]. bioRxiv, 2025: 2025.08. 18.670955.
[3]. Wu S, Wang N, Zhao L. Network pharmacology reveals the mechanism of activity of tongqiao huoxue decoction extract against middle cerebral artery occlusion-induced cerebral ischemia-reperfusion injury[J]. Frontiers in Pharmacology, 2021, 11: 572624.
[4]. Guo L, Lu T, Wang Y, et al. Inhibition of Acute Myeloid Leukaemia Development by Bittersweet Based on miR-let-7a Regulating Vascular Endothelial Growth Factor A Resistance Mechanism[J]. Journal of Biobased Materials and Bioenergy, 2024, 18(6): 1062-1068.
[5]. Lou Z, Li Q, Wang C, et al. The effects of microRNA-126 reduced inflammation and apoptosis of diabetic nephropathy through PI3K/AKT signalling pathway by VEGF[J]. Archives of physiology and biochemistry, 2022, 128(5): 1265-1274.
hVEGF-IN-1是一种喹唑啉衍生物（IRES-A：Kd = 0.928μM) [1]。通过降低VEGF-A蛋白表达，hVEGF-IN-1可有效阻断肿瘤细胞迁移并抑制肿瘤生长 [2]。hVEGF-IN-1主要用于研究VEGF-A介导的肿瘤血管生成 [3]。
在MDA-MB-231细胞中，hVEGF-IN-1（0.375-3μM；24h）使细胞迁移率降低了约25% [1]。在K562细胞中，hVEGF-IN-1（5μM；24h）上调miR-let-7a的表达并抑制VEGF-A的翻译 [4]。在NRK52E细胞中，hVEGF-IN-1（5μM；4h）抑制VEGF-A的表达 [5]。